| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| INCYIncyte Corporation | 20.66B | 105.24 | 701.60 | 14.76% | 24.69% | 25.55% | 1.21% | 0.01 |
| TGTXTG Therapeutics, Inc. | 4.88B | 30.71 | 204.73 | 40.8% | 13.31% | 21.87% | 1.14 | |
| AGIOAgios Pharmaceuticals, Inc. | 1.62B | 27.80 | 2.39 | 36.07% | -8.96% | -31.24% | 0.04 | |
| CLRBCellectar Biosciences, Inc. | 15.48M | 3.65 | -0.09 | -200.99% | 0.03 | |||
| CASICASI Pharmaceuticals, Inc. | 21.37M | 1.04 | -0.41 | -15.77% | -183.93% | -301.8% | 11.96 | |
| VORVor Biopharma Inc. | 308.06M | 14.06 | -0.41 | -94.52% | 0.33 | |||
| FATEFate Therapeutics, Inc. | 121.12M | 1.05 | -0.64 | -78.55% | -21.87% | -66.69% | 0.27 | |
| KPTIKaryopharm Therapeutics Inc. | 121.95M | 6.66 | -0.71 | -0.55% | -87.43% |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.8M | 1.14M | 2.34M | 0 | 33.92M | 209.91M | 69.56M | 70.84M |
| Revenue Growth % | - | -0.37% | 1.05% | -1% | - | 5.19% | -0.67% | 0.02% |
| Cost of Goods Sold | 85.53M | 118.09M | 0 | 141.82M | 1.39M | 3.3M | 2.53M | 5.95M |
| COGS % of Revenue | 47.44% | 103.58% | - | - | 0.04% | 0.02% | 0.04% | 0.08% |
| Gross Profit | -83.73M | -116.95M | 2.34M | -141.82M | 32.52M | 206.61M | 67.03M | 64.89M |
| Gross Margin % | -46.44% | -102.58% | 1% | - | 0.96% | 0.98% | 0.96% | 0.92% |
| Gross Profit Growth % | - | -0.4% | 1.02% | -61.61% | 1.23% | 5.35% | -0.68% | -0.03% |
| Operating Expenses | 93.47M | 127.08M | 121.74M | 77.45M | 294.24M | 329.95M | 233.01M | 195.54M |
| OpEx % of Revenue | 51.84% | 111.47% | 52.03% | - | 8.68% | 1.57% | 3.35% | 2.76% |
| Selling, General & Admin | 7.81M | 8.6M | 14.2M | 77.23M | 136.24M | 143.49M | 105.89M | 85.91M |
| SG&A % of Revenue | 4.33% | 7.55% | 6.07% | - | 4.02% | 0.68% | 1.52% | 1.21% |
| Research & Development | 85.53M | 118.31M | 107.54M | 142.03M | 158M | 186.46M | 127.13M | 109.63M |
| R&D % of Revenue | 47.44% | 103.78% | 45.96% | - | 4.66% | 0.89% | 1.83% | 1.55% |
| Other Operating Expenses | 137K | 166K | 0 | -141.82M | 0 | 0 | 0 | 0 |
| Operating Income | -91.67M | -125.94M | -119.4M | -219.26M | -261.72M | -123.34M | -165.99M | -130.65M |
| Operating Margin % | -50.84% | -110.47% | -51.03% | - | -7.72% | -0.59% | -2.39% | -1.84% |
| Operating Income Growth % | - | -0.37% | 0.05% | -0.84% | -0.19% | 0.53% | -0.35% | 0.21% |
| EBITDA | -91.33M | -125.43M | -117.75M | -218.44M | -259.09M | -120.96M | -162.72M | -127.38M |
| EBITDA Margin % | -50.65% | -110.02% | -50.32% | - | -7.64% | -0.58% | -2.34% | -1.8% |
| EBITDA Growth % | - | -0.37% | 0.06% | -0.86% | -0.19% | 0.53% | -0.35% | 0.22% |
| D&A (Non-Cash Add-back) | 341K | 513K | 1.65M | 821K | 2.63M | 2.39M | 3.27M | 3.28M |
| EBIT | -91.67M | -122.87M | -115.75M | -219.05M | -233.16M | -110.09M | -149.09M | -105.92M |
| Net Interest Income | 1.03M | 2.86M | 2.1M | -4.09M | -18.27M | -34.16M | -35.78M | -37.94M |
| Interest Income | 1.03M | 2.86M | 2.25M | 832K | 66K | 2.57M | 10.54M | 12.27M |
| Interest Expense | 0 | 0 | 156K | 4.93M | 18.34M | 36.73M | 46.33M | 50.21M |
| Other Income/Expense | 1.86M | 3.07M | 3.5M | -26.7M | 10.21M | -33.56M | -34.96M | -27.03M |
| Pretax Income | -89.81M | -122.87M | -115.9M | -245.96M | -251.5M | -156.9M | -200.95M | -157.68M |
| Pretax Margin % | -49.81% | -107.78% | -49.53% | - | -7.42% | -0.75% | -2.89% | -2.23% |
| Income Tax | 48K | 224K | 582K | 327K | -21.48M | 227K | 39.11M | 166K |
| Effective Tax Rate % | 1% | 1% | 1.01% | 1% | 0.91% | 1% | 1.19% | 1% |
| Net Income | -89.86M | -123.1M | -116.48M | -246.29M | -230.03M | -157.13M | -240.05M | -157.85M |
| Net Margin % | -49.84% | -107.98% | -49.78% | - | -6.78% | -0.75% | -3.45% | -2.23% |
| Net Income Growth % | - | -0.37% | 0.05% | -1.11% | 0.07% | 0.32% | -0.53% | 0.34% |
| Net Income (Continuing) | -89.86M | -123.1M | -116.48M | -246.29M | -230.03M | -157.13M | -240.05M | -157.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.53 | -2.29 | -1.74 | -3.77 | -3.00 | -1.99 | -2.94 | -1.62 |
| EPS Growth % | - | -0.5% | 0.24% | -1.17% | 0.2% | 0.34% | -0.48% | 0.45% |
| EPS (Basic) | -1.53 | -2.29 | -1.74 | -3.77 | -3.00 | -1.99 | -2.94 | -1.62 |
| Diluted Shares Outstanding | 58.85M | 53.83M | 66.87M | 65.41M | 76.75M | 78.15M | 81.71M | 97.16M |
| Basic Shares Outstanding | 58.85M | 53.83M | 66.87M | 65.41M | 76.75M | 78.15M | 81.71M | 97.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 265.17M | 142.08M | 122.61M | 450.45M | 525.18M | 434.98M | 336.29M | 307.39M |
| Cash & Short-Term Investments | 262.75M | 138.81M | 115.55M | 439.19M | 466.54M | 326.44M | 278.6M | 250.87M |
| Cash Only | 262.75M | 138.81M | 115.55M | 439.19M | 466.54M | 326.44M | 278.6M | 250.87M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.93M | 372K | 2.84M | 2.69M | 32.17M | 72.97M | 25.18M | 20.32M |
| Days Sales Outstanding | 390.1 | 119.11 | 442.99 | - | 346.16 | 126.89 | 132.14 | 104.68 |
| Inventory | 293K | 1.2M | 0 | 0 | 11.12M | 12.07M | 16.18M | 18.39M |
| Days Inventory Outstanding | 1.25 | 3.72 | - | - | 2.91K | 1.33K | 2.33K | 1.13K |
| Other Current Assets | 0 | 0 | 0 | 410K | 0 | 199K | 5.99M | 9.45M |
| Total Non-Current Assets | 6.78M | 8.48M | 15.08M | 63.24M | 92.79M | 55.88M | 18.49M | 14.59M |
| Property, Plant & Equipment | 1.14M | 1.54M | 6.27M | 4.76M | 11.23M | 10.26M | 16.13M | 13.43M |
| Fixed Asset Turnover | 1.58x | 0.74x | 0.37x | - | 3.02x | 20.46x | 4.31x | 5.27x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 5.4M | 6.67M | 8.43M | 10.18M | 13.58M | 14.36M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 47.91M | 41.24M | 7.61M | 1.65M | 0 |
| Other Non-Current Assets | 232K | 264K | 368K | 397K | 693K | -13.46M | 711K | 1.16M |
| Total Assets | 271.95M | 150.56M | 137.68M | 513.69M | 617.97M | 490.86M | 354.78M | 321.98M |
| Asset Turnover | 0.01x | 0.01x | 0.02x | - | 0.05x | 0.43x | 0.20x | 0.22x |
| Asset Growth % | - | -0.45% | -0.09% | 2.73% | 0.2% | -0.21% | -0.28% | -0.09% |
| Total Current Liabilities | 20.55M | 22.35M | 19.94M | 40.44M | 73.94M | 81.94M | 67.67M | 80.47M |
| Accounts Payable | 7.62M | 6.75M | 3.33M | 0 | 12.08M | 12.35M | 15.57M | 18.03M |
| Days Payables Outstanding | 32.51 | 20.86 | - | - | 3.17K | 1.37K | 2.25K | 1.11K |
| Short-Term Debt | 0 | 0 | 0 | 4.63M | 6.58M | 12.47M | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 834K | 23.59M | 14.11M | 4.08M | 37.94M | 47.47M |
| Current Ratio | 12.91x | 6.36x | 6.15x | 11.14x | 7.10x | 5.31x | 4.97x | 3.82x |
| Quick Ratio | 12.89x | 6.30x | 6.15x | 11.14x | 6.95x | 5.16x | 4.73x | 3.59x |
| Cash Conversion Cycle | 358.84 | 101.96 | - | - | 95.14 | 96.15 | 219.89 | 126.65 |
| Total Non-Current Liabilities | 2.24M | 1.96M | 6.58M | 137.75M | 377.95M | 329.47M | 435.36M | 444.15M |
| Long-Term Debt | 0 | 0 | 0 | 107.98M | 125.1M | 109.71M | 112.73M | 113.63M |
| Capital Lease Obligations | 0 | 0 | 3.9M | 2.46M | 6.99M | 6.56M | 10.18M | 8M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.08M | 1.39M | 2.68M | 3.76M | 222.32M | 189.65M | 312.45M | 2.43M |
| Total Liabilities | 22.78M | 24.32M | 26.53M | 178.19M | 451.88M | 411.41M | 503.03M | 524.62M |
| Total Debt | 0 | 0 | 5.03M | 115.08M | 139.7M | 129.85M | 124.38M | 123M |
| Net Debt | -262.75M | -138.81M | -110.52M | -324.11M | -326.85M | -196.59M | -154.22M | -127.87M |
| Debt / Equity | - | - | 0.05x | 0.34x | 0.84x | 1.63x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -765.38x | -44.51x | -14.27x | -3.36x | -3.58x | -2.60x |
| Total Equity | 249.17M | 126.24M | 111.16M | 335.5M | 166.09M | 79.45M | -148.25M | -202.64M |
| Equity Growth % | - | -0.49% | -0.12% | 2.02% | -0.5% | -0.52% | -2.87% | -0.37% |
| Book Value per Share | 4.23 | 2.35 | 1.66 | 5.13 | 2.16 | 1.02 | -1.81 | -2.09 |
| Total Shareholders' Equity | 249.17M | 126.24M | 111.16M | 335.5M | 166.09M | 79.45M | -148.25M | -202.64M |
| Common Stock | 397K | 401K | 4.36M | 6.31M | 6.45M | 7.31M | 7.31M | 8.43M |
| Retained Earnings | -208.99M | -332.08M | -448.57M | -694.86M | -924.88M | -1.1B | -1.34B | -1.49B |
| Treasury Stock | 0 | 0 | -100K | -4K | -128K | -679K | -541K | -220K |
| Accumulated OCI | 5.46M | 5.66M | 5.54M | 43M | 102.83M | 1.82M | -93K | -1.42M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -74.94M | -121.36M | -121.58M | -168.73M | -233.38M | -138.31M | -118.69M | -123.83M |
| Operating CF Margin % | -41.57% | -106.46% | -51.96% | - | -6.88% | -0.66% | -1.71% | -1.75% |
| Operating CF Growth % | - | -0.62% | -0% | -0.39% | -0.38% | 0.41% | 0.14% | -0.04% |
| Net Income | -89.86M | -123.1M | -116.48M | -246.29M | -230.03M | -157.13M | -240.05M | -157.85M |
| Depreciation & Amortization | 341K | 740K | 1.65M | 2.19M | 2.63M | 5.74M | 3.27M | 3.28M |
| Stock-Based Compensation | 980K | 469K | 1.12M | 37.59M | 60.48M | 50.64M | 13.49M | 6.57M |
| Deferred Taxes | 48K | 935K | 1.21M | 327K | -26.05M | 0 | 37.1M | 0 |
| Other Non-Cash Items | 36K | -891K | -1.19M | 25.1M | -24.7M | 11.47M | 23.23M | 20.34M |
| Working Capital Changes | 13.51M | 481K | -7.88M | 12.36M | -15.71M | -49.03M | 44.27M | 3.83M |
| Change in Receivables | 4.82M | 895K | 192K | 0 | -30.22M | -42.75M | 47.79M | 4.77M |
| Change in Inventory | 5.03M | 1.58M | -2.31M | 0 | -3.02M | -9.65M | -5.71M | -3.73M |
| Change in Payables | 5.47M | -858K | -3.42M | 1.92M | 6.8M | 0 | 3.17M | 2.46M |
| Cash from Investing | -3.25M | -2.51M | -2.25M | -2.83M | -6.67M | -687K | -3.22M | -867K |
| Capital Expenditures | -3.16M | -2.47M | -2.15M | -2.81M | -3.43M | -687K | -3.22M | -867K |
| CapEx % of Revenue | 1.75% | 2.17% | 0.92% | - | 0.1% | 0% | 0.05% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -92K | -36K | -100K | -19K | -3.24M | 0 | 0 | 0 |
| Cash from Financing | 197.24M | -24K | 100.51M | 494.97M | 267.39M | -897K | 73.88M | 97.05M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -24K | 101.66M | 54K | 218.78M | 3.13M | 73.88M | 36.55M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -78.1M | -123.83M | -123.73M | -171.54M | -239.75M | -139M | -121.9M | -124.7M |
| FCF Margin % | -43.32% | -108.62% | -52.88% | - | -7.07% | -0.66% | -1.75% | -1.76% |
| FCF Growth % | - | -0.59% | 0% | -0.39% | -0.4% | 0.42% | 0.12% | -0.02% |
| FCF per Share | -1.33 | -2.30 | -1.85 | -2.62 | -3.12 | -1.78 | -1.49 | -1.28 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.99x | 1.04x | 0.69x | 1.01x | 0.88x | 0.49x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 10.18M | 15.39M | 15.7M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -36.07% | -65.58% | -98.13% | -110.28% | -91.72% | -127.99% | - | - |
| Return on Invested Capital (ROIC) | - | - | -14080.07% | -2734.63% | - | - | - | - |
| Gross Margin | -4643.76% | -10258.42% | 100% | - | 95.89% | 98.43% | 96.36% | 91.6% |
| Net Margin | -4984.03% | -10797.89% | -4977.95% | - | -678.2% | -74.86% | -345.11% | -222.83% |
| Debt / Equity | - | - | 0.05x | 0.34x | 0.84x | 1.63x | - | - |
| Interest Coverage | - | - | -765.38x | -44.51x | -14.27x | -3.36x | -3.58x | -2.60x |
| FCF Conversion | 0.83x | 0.99x | 1.04x | 0.69x | 1.01x | 0.88x | 0.49x | 0.78x |
| Revenue Growth | - | -36.77% | 105.26% | -100% | - | 518.89% | -66.86% | 1.84% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Product | - | - | 69.06M | 69.28M |
| Product Growth | - | - | - | 0.32% |
| Royalty Revenue | - | - | 498K | 1.56M |
| Royalty Revenue Growth | - | - | - | 212.65% |
| License Revenues | - | - | - | - |
| License Revenues Growth | - | - | - | - |
| Contract Revenue | - | 135M | - | - |
| Contract Revenue Growth | - | - | - | - |
| Product Revenue | 33.92M | 74.91M | - | - |
| Product Revenue Growth | - | 120.86% | - | - |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| UNITED STATES | - | - | 69.06M | 69.28M |
| UNITED STATES Growth | - | - | - | 0.32% |
| EMEA | - | - | 498K | 1.56M |
| EMEA Growth | - | - | - | 212.65% |
| JAPAN | - | - | - | - |
| JAPAN Growth | - | - | - | - |
ADC Therapeutics S.A. (ADCT) reported $75.2M in revenue for fiscal year 2024. This represents a 4071% increase from $1.8M in 2017.
ADC Therapeutics S.A. (ADCT) grew revenue by 1.8% over the past year. Growth has been modest.
ADC Therapeutics S.A. (ADCT) reported a net loss of $166.9M for fiscal year 2024.
ADC Therapeutics S.A. (ADCT) had negative free cash flow of $132.3M in fiscal year 2024, likely due to heavy capital investments.